TheraRadar

Pharma Intelligence, Simplified

Landscape → Immunology

Crohn's Disease

333 clinical trials

132 active
/
333 total (since 2015)
25
Phase 1 Active
75 total
52
Phase 2 Active
129 total
43
Phase 3 Active
98 total
31
Phase 4 Active
67 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Takeda 13 14 8
Johnson & Johnson 9 6 4
AbbVie 7 9 1
Sanofi 5 0 0
Roche 4 2 3
Eli Lilly 4 2 0
AstraZeneca 3 2 3
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. 2 1 0
Merck 2 0 0
Direct Biologics, LLC 1 0 2
Agomab Spain S.L.U. 1 1 0
Abivax S.A. 1 0 1
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) 1 0 0
Palisade Bio 1 0 0
Teva Branded Pharmaceutical Products R&D LLC 1 0 0
NCT07196722 RECRUITING
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=1,092
NCT04844606 RECRUITING
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company n=150
NCT05509777 RECRUITING
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company n=90
NCT07184931 RECRUITING
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi n=980
NCT07184944 RECRUITING
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi n=671
NCT06937099 RECRUITING
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company n=290
NCT06430801 RECRUITING
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Merck Sharp & Dohme LLC n=1,200
NCT07298421 NOT YET RECRUITING
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=100
NCT05347095 ACTIVE NOT RECRUITING
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Janssen-Cilag Ltd. n=288
NCT05197049 ACTIVE NOT RECRUITING
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=350
NCT06408935 RECRUITING
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Janssen-Cilag Ltd. n=112
NCT06819891 RECRUITING
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=425
NCT06663332 RECRUITING
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC n=196
NCT03466411 ACTIVE NOT RECRUITING
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=1,409
NCT05995353 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie n=118
NCT06819878 RECRUITING
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=600
NCT05092269 RECRUITING
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development, LLC n=151
NCT05923073 RECRUITING
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=120
NCT06651281 RECRUITING
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme LLC n=1,380
NCT06332534 RECRUITING
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
AbbVie n=110
NCT04232553 ACTIVE NOT RECRUITING
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company n=996
NCT06405087 RECRUITING
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda n=70
NCT05837897 RECRUITING
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Takeda n=408
NCT04779320 RECRUITING
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Takeda n=120
NCT06274554 RECRUITING
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Weill Medical College of Cornell University n=120
NCT06100289 RECRUITING
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda n=70
NCT07177118 NOT YET RECRUITING
Risankizumab for Fibrostenotic Crohn's Disease Treatment
First Affiliated Hospital of Wenzhou Medical University n=260
NCT06063967 ACTIVE NOT RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie n=289
NCT03105102 ACTIVE NOT RECRUITING
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie n=1,336
NCT04524611 ACTIVE NOT RECRUITING
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
AbbVie n=527
NCT04997733 RECRUITING
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
Assistance Publique - Hôpitaux de Paris n=150
NCT03345823 ACTIVE NOT RECRUITING
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie n=747
NCT04738942 ACTIVE NOT RECRUITING
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Takeda n=57
NCT06227910 RECRUITING
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Takeda n=396
NCT05040464 RECRUITING
Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
Centre Hospitalier Universitaire, Amiens n=166
NCT06925594 RECRUITING
Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. n=228
NCT05442567 RECRUITING
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda n=240
NCT05299931 ACTIVE NOT RECRUITING
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW n=108
NCT05660746 RECRUITING
Precise Infliximab Exposure and Pharmacodynamic Control
Children's Hospital Medical Center, Cincinnati n=180
NCT06719622 ENROLLING BY INVITATION
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
Medical University of Warsaw n=114
NCT04777656 RECRUITING
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
Assistance Publique - Hôpitaux de Paris n=120
NCT05284136 NOT YET RECRUITING
Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease
Assistance Publique - Hôpitaux de Paris n=80
NCT04398836 NOT YET RECRUITING
Preoperative Nutrition for Crohn's Disease Patients
Tel-Aviv Sourasky Medical Center n=144
NCT04397263 COMPLETED
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Pharmaceutical K.K. n=38
NCT04673357 COMPLETED
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=101
NCT04701411 TERMINATED
A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease
Takeda n=7
NCT03440372 TERMINATED
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=625
NCT03464097 TERMINATED
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=550
NCT03467958 TERMINATED
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Celgene n=854
NCT04173273 TERMINATED
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Pfizer n=375
NCT03782376 COMPLETED
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen-Cilag Ltd. n=215
NCT03107793 COMPLETED
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Janssen-Cilag Ltd. n=500
NCT05784129 TERMINATED
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Janssen Research & Development, LLC n=4
NCT03464136 COMPLETED
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Janssen Scientific Affairs, LLC n=386
NCT04075825 COMPLETED
Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Takeda n=150
NCT05470985 TERMINATED
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
Bristol-Myers Squibb n=5
NCT02620046 COMPLETED
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Takeda n=746
NCT03926130 COMPLETED
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company n=1,158
NCT04974099 TERMINATED
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Children's Hospital Medical Center, Cincinnati n=6
NCT03440385 COMPLETED
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=606
NCT02403323 TERMINATED
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Hoffmann-La Roche n=790
NCT04245215 COMPLETED
Loss of RESponse to Ustekinumab Treated by Dose Escalation
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW n=108
NCT04060303 COMPLETED
ENhanced Recovery in CHildren Undergoing Surgery
Northwestern University n=599
NCT03279081 COMPLETED
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
Tigenix S.A.U. n=568
NCT03905109 WITHDRAWN
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Abivax S.A.
NCT02914600 TERMINATED
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Galapagos NV n=1,188
NCT03283085 COMPLETED
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Shire n=557
NCT03706456 COMPLETED
Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease
Takeda n=22
NCT05104229 WITHDRAWN
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Stefan Holubar MD MS FACS, FASCRS
NCT02914561 COMPLETED
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Galapagos NV n=1,372
NCT03759288 TERMINATED
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
AstraZeneca n=89
NCT03961815 TERMINATED
Open-label Extension Study of Brazikumab in Crohn's Disease
AstraZeneca n=18
NCT03945019 COMPLETED
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Celltrion n=396
NCT02772965 COMPLETED
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
University of North Carolina, Chapel Hill n=306
NCT03234907 COMPLETED
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
Takeda n=215
NCT02769494 WITHDRAWN
The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer
Xijing Hospital of Digestive Diseases
NCT03345849 COMPLETED
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
AbbVie n=526
NCT02394028 COMPLETED
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=1,035
NCT03345836 COMPLETED
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
AbbVie n=624
NCT03105128 COMPLETED
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
AbbVie n=931
NCT03104413 COMPLETED
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
AbbVie n=618
NCT02611817 COMPLETED
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Takeda n=644
NCT03627091 TERMINATED
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Shire n=40
NCT04643483 WITHDRAWN
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
UCB Biopharma SRL
NCT03566823 TERMINATED
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Shire n=34
NCT03559517 TERMINATED
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Shire n=30
NCT03009396 COMPLETED
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
RedHill Biopharma Limited n=54
NCT02680756 COMPLETED
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics n=250
NCT02186275 COMPLETED
The Vitamin D in Pediatric Crohn's Disease
St. Justine's Hospital n=25
NCT03221166 TERMINATED
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
IRCCS Burlo Garofolo n=9
NCT02871635 COMPLETED
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Boehringer Ingelheim n=147
NCT03467620 WITHDRAWN
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
University of Illinois at Chicago
NCT03357471 COMPLETED
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Biopharma S.P.R.L. n=70
NCT02596893 TERMINATED
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Celgene n=701
NCT02641392 TERMINATED
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
Celgene n=310
NCT02499783 COMPLETED
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie n=205
NCT02425111 COMPLETED
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Takeda n=101
NCT02974322 WITHDRAWN
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Celgene

Data: ClinicalTrials.gov